Prospective, Multi-country, Observational Registry to Collect Clinical Information on Patients With Endogenous Cushing's Syndrome to Assess Drug Utilization Pattern and to Document the Safety and Effectiveness of Ketoconazole.
Latest Information Update: 25 Sep 2021
Price :
$35 *
At a glance
- Drugs Ketoconazole (Primary)
- Indications Cushing syndrome
- Focus Adverse reactions
- Acronyms KetoPASS
- Sponsors HRA Pharma
- 11 May 2021 New trial record